When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?

It depends on what previous therapies have been used. If this patient has already progressed on anti-PD1 monotherapy and BRAF/MEK inhibitor, then TIL therapy should be explored. I would use IPI-3 and NIVO-1 as a bridge in that scenario, after harvest (can start before harvest as well if a date is no...